Immunotherapy Publications:

Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy. 2010 Mar;2(2):137-40.

Nicodemus CF, Wang L, Lucas J, Varghese B, Berek JS. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010 Jun;202(6):608.e1-8.

Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25.

Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother. 2009 Jan;32(1):54-65.

Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167-89.

Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009 Mar;58(3):317-24.

Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008 Feb-Mar;31(2):207- 14.

Nicodemus CF, Smith LM, Schultes BC. Role of monoclonal antibodies in tumor-specific immunity. Expert Opin Biol Ther. 2007 Mar;7(3):331-43.

Nicodemus CF, Berek JS. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther. 2005 Feb;5(1):87-96.

Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004 Sep 1;22(17):3507-16.

Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51.

Schultes BC, Nicodemus CF. Using antibodies in tumour immunotherapy. Expert Opin Biol Ther. 2004 Aug;4(8):1265-84.

de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.

Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol. 2003 Jul;189(1):28-36.

Schultes BC, Whiteside TL. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J Immunol Methods. 2003 Aug;279(1-2):1- 15.

Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s.

Berek JS, Dorigo O, Schultes B, Nicodemus C. Specific keynote: immunological therapy for ovarian cancer. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S105-9; discussion S110-3.

Nicodemus CF, Schultes BC, Hamilton BL. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Expert Rev Vaccines. 2002 Jun;1(1):35-48.

Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol. 2001 Dec;101(3):276-83.

Schultes BC, Agopsowicz K, Kuzma M, Nicodemus CF, Noujaim AA, Mann DL. Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells – a novel strategy for cancer immunotherapy. Proc AACR (2001) 42:276

Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13- -evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm. 2001 Jun;16(3):187-203.

Schultes BC, Zhang C, Xue LY, Noujaim AA, Madiyalakan R. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL- SCID/BG mouse model. Hybridoma 1999 Feb;18(1):47-55.

Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, Garinther WI, Schultes BC, Noujaim AA, Madiyalakan R, Magnani J, Nilsson O, Nilsson K, Nustad K, Norum L, Bell H, Cao Y, Suresh MR, Very DL, Freeman JV, Yeung KK, Hilgers J. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997. Tumour Biol. 1998;19(5):390-420.

Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother. 1998 Jun;46(4):201-12.

McQuarrie SA, Riauka T, Baum RP, Sykes TR, Noujaim AA, Boniface G, MacLean GD, McEwan AJ. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients. J Pharm Pharm Sci. 1998 Sep-Dec;1(3):115- 25.

Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA. OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma 1997 Feb;16(1):41-5.

McQuarrie SA, Baum RP, Niesen A, Madiyalakan R, Korz W, Sykes TR, Sykes CJ, Hör G, McEwan AJ, Noujaim AA. Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients. Nucl Med Commun. 1997 Sep; 18(9):878-86.

Madiyalakan R, Kuzma M, Noujaim AA, Suresh MR. An antibody-lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients. Glycoconj J. 1996 Aug;13(4):513-7.

Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, Noujaim AA. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.Hybridoma 1995 Apr;14(2):199-203.

Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.Cancer. 1994 Feb 1;73(3 Suppl):1121-5

Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 1993 Oct;12(5):583-9.

Berek J.S.  Immunotherapy of Ovarian cancer with antibodies:  a focus on Oregovomab Expert Opinion of Biological Therapy 2004; 4:1159-1165

Qi W, Schultes BC, Liu D, Kuzma M, Decker W, Madiyalakan R. Characterization of an anti- MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics 20(5-6):313-24, 2001.

Tremayne J, Schultes B, Eggers J, Hou F, Daley G, Hollingsworth MA. Treatment of pancreatic cancer with combination of MAb-AR20.5 and gemcitabine in a murine orthotopic model. 2011In press.

Sonolight Technology:

Z. Diwu, J.W. Lown. Hypocrellins and their use in photosensitization. Photobiol. Photochem 52:3, 609-616, 1990.

Z. Diwu, J.W. Lown. Phototherapeutic potential of alternative photosensitizers to porphyrins. Ther Pharmacol 63:1, 1-35, 1994.

Z. J. Diwu, J. W. Lown, Photosensitization with anticancer agents 12, Perlyenequinoid pigments, a novel type of singlet oxygen sensitizer, J. Photochem. Photobiol. A: Chem. 64 (1992), 273 – 287.

Z. Diwu, C. Zhang, J.W. Lown. Photosensitization with anticancer agents. XIII. The production of singlet oxygen by halogenated and metal-ion- chelated perylenequinones. J photochem photobiol A, Chemistry 66:1, 99-112, 1992.

Z. Diwu, J.W. Lown. Photosensitization with anticancer agents. 15. Perylenequinonoid pigments as potential photodynamic therapeutic agents: formation of semiquinone radicals and reactive oxygen species on illumination. J Photochem Photobiol B 18:2-3, 131-143, 1993.

Jixiang Liu, J., Gerald G. Miller, Liren Huang, Zhenjun J. Diwu, J. William Lown, Kevin Brown, Ronald B. Moore, John Tulip, and Malcolm S. McPhee. Synthesis and biodistribution of 14C-radiolabelled hypocrellin B. J. Labelled Compounds and Radiopharmaceuticals. XXXVI (9): 815-823, 1995.

Gerald G. Miller, Kevin Brown, Ronald B. Moore, Zhenjun J. Diwu, Jixiang Liu, Liren Huang, J.William Lown, David A. Begg, Vera Chlumecky, John Tulip, and Malcolm S. McPhee. Intracellular uptake kinetics of hypocrellin photosensitizers for photodynamic therapy.  SPIE Proceedings of the 5th Biennial Photodynamic Therapy Society Meeting. 2371: 97-101, 1995.

Åse M. Ballangrud, Peter Wilson, Gerald G. Miller, Ronald B. Moore, Malcolm S. McPhee, andJohn Tulip. Light distribution and optical coefficients in prostate tumor. SPIE Proceedings of the 5th Biennial Photodynamic Therapy Society Meeting. 2371: 148-152, 1995.

G.G. Miller, K. Brown, R.B. Moore, Z.J. Diwu, J. Liu, L. Huang, J.W. Lown, D.A. Begg, V. Chlumecky, J. Tulip and M.S. McPhee.  Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: A confocal microscopy study. Photochem. Photobiol. 61:6, 632-638, 1995.

Estey, E.P., Brown, K., Diwu, Z., Lown, J.W., Miller, G.G., Moore, R.B., Tulip, J., and M.S. McPhee. Hypocrellins as photosensitizers for photodynamic therapy: A screening evaluation. Cancer Chemotherapy and Pharmacology 37: 343-350, 1996.

Zhenjun Diwu, Jixiang Liu, J. William Lown, Gerald G. Miller, Ronald B. Moore, Kevin Brown, John Tulip, and Malcolm S. McPhee. Photosensitization by anticancer agents. Part 21: New perylenequinone and aminonaphthoquinone photosensitizers. Free Radical Biology & Medicine 20(4): 589-593, 1996.

Åse M. Ballangrud, Peter J. Wilson, Kevin Brown, Gerald G. Miller, Ronald B. Moore, Malcolm S. McPhee, and John Tulip.  Anisotropy of radiance in tissue phantoms and Dunning R3327 rat tumors: Radiance measurements with flat cleaved fiber probes. Lasers in Surgery and Medicine, 19:4 471-479, 1996.

Åse M. Ballangrud, Oscar Barajas, Alexia Georgousis, Gerald G. Miller, Ronald B. Moore, Malcolm S. McPhee, and John Tulip.  In vivo light transmission spectra in EMT6/Ed murine tumors and Dunning R3327 rat prostate tumors during photodynamic therapy. Lasers in Surgery and Medicine 21(2): 124-133, 1997.

Oscar Barajas, Åse M. Ballangrud, Gerald G. Miller, Ronald B. Moore, John Tulip. Monte Carlo modelling of angular radiance in tissue phantoms and human prostate: PDT light dosimetry. Physics in Medicine and Biology 42(9): 1675-1687, 1997.

Y. Xie, G.G. Miller, S. Cubitt, K.J. Soderlind, L. Huang, M.J. Allalunis-Turner, and J.W. Lown Enediyne-Lexitropsin DNA-targeted anticancer agents 1: Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution. Anti-Cancer Drug Design, 12: 169-179, 1997.

Åse M. Ballangrud, Oscar Barajas, Kevin Brown, Gerald G. Miller, Ronald B. Moore, John Tulip. Temporal and illumination-induced variations in the in vivo light transmission spectra of four photosensitizers in EMT6/Ed murine tumors. Lasers in Medical Science 12(3): 237-244, 1997.

G.G Miller, K. Brown, Å.M. Ballangrud, R.B. Moore, O. Barajas, Z. Xiao, J. Tulip, J.M. Leithoff, M.J. Allalunis-Turner, Ram D. Mehta, and J.W. Lown.  Preclinical Assessment of Hypocrellin B and HB Derivatives as Sensitizers for Photodynamic Therapy of Cancer: Progress Update. Photochemistry & Photobiology, 65(4): 714-722, 1997.

Gerald G. Miller and J. William Lown, Immuno-Photodynamic Therapy: Current Developments and Future Prospects, Drug Development Research. (Invited review) 42: 182-197, 1997.

Krista-June Soderlind, Brian Gorodetsky, Ashok K. Singh, Nicholas R Bachur, Gerald G Miller, and J William Lown. Bis-benzimidazole anticancer agents: targetting human tumour helicases, Anti-Cancer Drug Design 14: 19-36, 1999.

Zhengwen xiao, christian b. hansen, 3, Theresa m. Allen, Gerald G. Miller and r. distribution of Photosensitizers in Bladder Cancer Spheroids: Implications for Intravesical Instillation of Photosensitizers for Photodynamic Therapy of Bladder Cancer. moore, J Pharm Pharmaceut Sci ( 8(3):536-543, 2005

El-Sikhry HE, Miller GG, Madiyalakan MR, Seubert JM.Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acid Invest New Drugs. 2011 Dec;29(6):1328-36.

Xiao Z, Owen RJ, Liu W, Tulip J, Brown K, Woo T, Moore RB Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Photodiagnosis Photodyn Ther. 2010 Jun;7(2):106-14.

Korbelik M, Merchant S, Huang N. Exploitation of immune response-eliciting properties of hypocrellin photosensitizer SL052-based photodynamic therapy for eradication of malignant tumors. Photochem Photobiol. 2009 Nov-Dec;85(6):1418- 24.

Meng Y, Zou C, Madiyalakan R, Woo T, Huang M, Yang X, Swanson E, Chen J, Xing JZ. Water-soluble and biocompatible sono/photosensitizer nanoparticles for enhanced cancer therapy. Nanomedicine (Lond). 2010 Dec;5(10):1559-69.

Intra-arterial Targeted Delivery of Lipophilic Photosensitizer for Photodynamic Therapy of Prostate Cancer. Xiao J, Owen RJ, RB Moore In: Photosensitizer for Photodynamic Therapy of Prostate Cancer. Nova Science Publishers, Inc; In Publication 2010 (Book Chapter). Mladen Korbelik, Ragupathy Madiyalakan, Thomas Woo and Azita Haddadi. Antitumor Efficacy of Photodynamic Therapy Using 1 Novel Nanoformulations of Hypocrellin Photosensitizer SL052. Photochem Photobiol. 2011 In press